[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:kit-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"KIT Gene",13,12,[8,16,22,29,36,43,49,55,61,67,73,79,85],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07218926","A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy",[12],"Phase 3","RECRUITING","2026-08-26T02:17:21.315591Z","2026-07-05T05:32:16.663184Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05208047","(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors",[12],"2026-08-26T02:18:45.196599Z","2026-06-17T02:29:30.056293Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07171203","Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor",[26],"Phase 1","2026-08-26T02:17:00.709807Z","2026-06-16T05:54:07.933748Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06630234","A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)",[33],"Phase 1\u002FPhase 2","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:29.051332Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05366816","ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST",[40],"Phase 2","2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.815567Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT07406633","KQB198 in Combination With Imatinib in Participants With Advanced\u002FMetastatic GIST in 1st Line Setting",[40],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:27.814895Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06655246","A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)",[26],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:27.645419Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05493215","Imatinib TDM in GIST",[40],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:27.434422Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05957367","A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies",[33],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:26.929806Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04598009","Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",[40],"2026-08-26T02:19:21.761002Z","2026-04-29T02:57:57.109334Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[40],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04996875","(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis",[40],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.251075Z",{"nct_id":86,"title":87,"phases":88,"status":89,"updated_at":90,"content_modified":91},"NCT05489237","First-in-human Study of IDRX-42 in Participants With Metastatic and\u002For Unresectable Gastrointestinal Stromal Tumors",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:33:02.530589Z","2026-05-05T02:43:29.679210Z"]